Radiotherapy Treatments for the Treatment of Thoracic District Tumors

Status Recruiting

Clinical Trial Summary

Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of thoracic radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the thoracic anatomical region.

Clinical Trial Description

Approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment. Various primary tumors as well as metastases of various origins can be localized in the thoracic anatomical region. Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments. Treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects. The collection of data related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies. This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms of the thoracic region for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols. ;

Study Design

Related Conditions & MeSH terms

Thoracic Neoplasms

Clinical Trial Details

NCT number	NCT06335290
Study type	Observational
Source	European Institute of Oncology
Contact	Barbara Alicja Jereczek
Phone	+39 02 57489326
Email	barbara.jereczek@ieo.it
Status	Recruiting
Phase
Start date	February 22, 2018
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT02909452` - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04741958` - Role of Ultrasound Guided Peripheral Thoracic Tumors	N/A
Recruiting	`NCT04556344` - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer	N/A
Terminated	`NCT03306693` - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers	N/A
Completed	`NCT04751552` - Erector Spinae Block for Thoracoscopic Surgery	N/A
Not yet recruiting	`NCT06104774` - The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery	N/A
Completed	`NCT05770869` - mHealth ALIBIRD: A Digital Health Care Model	N/A
Recruiting	`NCT04589247` - Improving Cancer Symptom Management
Not yet recruiting	`NCT04133337` - Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC	Phase 1/Phase 2
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Completed	`NCT02188563` - A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers	N/A
Completed	`NCT03134872` - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	Phase 3
Not yet recruiting	`NCT04371796` - Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC	Phase 2
Completed	`NCT00437372` - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients	Phase 1
Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04862780` - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Phase 1/Phase 2
Recruiting	`NCT04776447` - Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)	Phase 2
Recruiting	`NCT05988736` - Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.	N/A
Not yet recruiting	`NCT06376084` - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC